Intestinal Candida albicans is Associated with Subclinical Coronary Atherosclerosis in Metabolic Dysfunction-associated Steatotic Liver Disease with Cirrhosis

Key Points

• Subclinical coronary atherosclerosis is associated with the gut mycobiome in metabolic dysfunction-associated steatotic liver disease.
• The association highlights the potential influence of intestinal fungi on cardiovascular disease risk.
• Investigation into the gut mycobiome reveals insights into its role in atherosclerosis.
• These findings may lead to new approaches in managing cardiovascular health related to liver disease.